Isarna Initiates First-in-Human Phase I Trial for ISTH0036 to Treat Advanced Glaucoma
21-Apr-2015 -
Isarna Therapeutics announced the initiation of a Phase I clinical trial with ISTH0036, an antisense oligonucleotide selectively targeting TGF-ß2 to treat advanced glaucoma.This first-in-human Phase I trial, conducted at the University Hospitals of Mainz and Tuebingen, Germany, is designed to ...
blindness
glaucoma
oligonucleotides
+1